Llwytho...
Ocular adverse events with immune checkpoint inhibitors
PURPOSE: To quantify the risk of ocular adverse events with immune checkpoint inhibitors (ICIs) as reported to the Food and Drug Administration (FDA). METHODS: Disproportionality analysis using data from U.S. FDA's Adverse Events Reporting System (FAERS) database 2003 to 2018. Data from pharmac...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Curr Ophthalmol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Elsevier
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6742617/ https://ncbi.nlm.nih.gov/pubmed/31528768 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.joco.2019.05.002 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|